Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward normal.
Telomir Pharmaceuticals is a cancer-focused company. Its clinical work is aimed at breast cancer, so a paper about failing eyesight in fish is a slightly odd thing to see under its name. The Nasdaq-listed biotech (ticker TELO) has just announced one anyway. The results are interesting enough to look at closely, though they need a fair amount of squinting at what they can and can’t tell us.
The study, published in the International Journal of Molecular Sciences, tested the company’s lead compound, Telomir-Zn, in a zebrafish model of mitochondrial dysfunction and age-related retinal degeneration, which the company presents as a model of age-related macular degeneration (AMD). AMD is an eye disease tied to getting older. Untreated fish in the model had profound vision problems, lost light-sensing cells and showed damage across several layers of the retina [1].
What happened in the fish
After 14 days of oral treatment, the fish improved on three measures: their central visual response, their ability to track moving objects and how well they adjusted to changes in light. Under the microscope, the thickness of multiple retinal layers had been restored, according to the company.
The team also looked at oxidative stress, which is a bit like cellular rust. Cells produce reactive molecules as a byproduct of running their engines (the mitochondria), and when the engines are damaged, those molecules pile up. The AMD model showed markedly elevated levels. Telomir-Zn brought them down, and the higher dose pushed values back toward those of healthy fish. One detail worth flagging is that the researchers measured this in the fish’s brain and used it as a stand-in for mitochondrial stress generally. The release doesn’t mention a direct reading from the retina.
In a separate experiment with human retinal pigment cells grown in a dish, the compound eased the calcium disruption triggered by iron and copper, and lowered the cell stress caused by copper, with bigger doses doing more.
Telomeres and epigenetics
This is where the longevity crowd will lean in. Telomeres are protective caps on the ends of chromosomes, and they’re closely tied to cellular aging. In the fish model, telomere content was significantly lower than in healthy animals. After treatment, it rose toward the healthy profile, and higher doses moved it further. The compound was also linked to restoration of altered DNA methylation patterns at selected spots associated with aging. Methylation, roughly speaking, is a set of chemical tags that helps decide which genes get switched on.
The company’s explanation runs through iron. Telomir-Zn increased zinc inside cells while lowering a reactive form of iron, and it also inhibited a group of iron-dependent enzymes (called KDMs) that help control which genes are active. Because those enzymes need iron to work, less available iron could mean less activity from them. Telomir had already reported something similar in triple-negative breast cancer cells, where adding iron back reversed the compound’s anti-cancer effect.
“This study gives us an important new view of the relationship between intracellular metal balance, oxidative stress, epigenetic regulation and retinal degeneration,” said Dr Itzchak Angel, Chief Scientific Advisor of Telomir. “Telomir-Zn significantly improved visual function, reduced retinal degeneration, and restored key retinal-layer thicknesses, supporting the potential relevance in a devastating disease such as AMD, beyond oncology.”
How far to trust a fish
Some perspective is needed. This is a preclinical study in zebrafish and a cell line, and the announcement comes from the company itself. The release describes no testing of Telomir-Zn in people with an eye disease, and the company says its clinical priority remains oncology. That work is a Phase 1/2 trial in advanced or metastatic triple-negative breast cancer, backed by an FDA-cleared Investigational New Drug application. The word “restored” also deserves a gentle read. Several markers are described as moving toward the healthy profile, and the release doesn’t claim they got all the way there.
There’s a second, more subtle question. Telomir argues that one compound working in cancer and in the eye points to a shared mechanism around metal balance and epigenetics. That’s plausible. A compound that touches something as basic as iron handling might also simply do a lot of things, and the current data can’t separate those two readings.
“Our clinical priority remains oncology, beginning with our FDA-cleared Phase 1/2 program in TNBC, but we believe the potential opportunity for Telomir-Zn could extend well beyond a single indication,” said Erez Aminov, CEO of Telomir. “As we build evidence across different disease models, we are seeing a common biology centered on intracellular metal homeostasis and epigenetic regulation. We believe this creates meaningful platform potential for Telomir-Zn across additional cancers and, over time, other diseases where this biology may play an important role.”
For anyone watching the aging field, the appeal is the overlap. Oxidative stress, tired mitochondria, shortened telomeres and drifting methylation are all themes that keep turning up in aging research, and a single lever touching several of them would be worth chasing. Whether iron is that lever in people is something later studies will need to show.
[1] https://ir.telomirpharma.com/single-news-releases/?storyId=8287290379542809
